Many companies have achieved success as a result of outlining their future operations and growth guidance which must also be in line with the ongoing projects. Cash flow projections, as well as current historical market advancements, are also key indicators of what the company is likely to deliver. This analysis is what has driven Cannabis Science Inc (OTCMKTS:CBIS) into providing its direction given that the industry has shown high-growth potential and a heightened release of new drugs.

Besides, legislators are putting every effort to have cannabis legalize for medical purposes a move that could give grow the market up to ten times. The growth would further translate to over US$300 Billion but only if the FDA certified clinical trials access and increased pre-clinical study.

Projection of cannabis industry advancements

There is a high expectation of positive results from the upcoming November voting in California. Many are a foreseeing relaxation of laws which will allow access to medical marijuana through at a precise age specifications. The projected market increase of 100 – 1,000 times could propel the California Cannabis industry to well over US$750 Billion.

There has been a lot of push and pull between the Federal authority, hundreds of cannabis users and their advocates. While the administration categorically outlines that marijuana is illegal, the supporters say it is the only option of treatment critical ailments that have failed to adhere to the regular prescriptions. Nevertheless, they have remained optimistic that the November voting will outdo most of the current laws which will likely expand the market.

CBIS gets ready for the expected growth explosion

CBIS is willing to recapture even as little as 1% of the market. To back up its preparations for the market expansion, the company has moved its headquarters to Irvine, California whereby it describes the location as strategic. It has also initiated talks with a Los Angeles area laboratory/medical clinic alongside pre-clinical trials for five important drugs whose target is cancer, HIV/AIDS, and a range of other endemic neurological disorders.

The recent phase three testing of a CBD-based product by GW Pharmaceuticals is also encouragement for Cannabis Science given that is also looking forward to carrying out its tests in Europe and the United States. Applauding GW Pharmaceutical’s success, Raymond C. Dabney, President and CEO of Cannabis Science, Inc said the success would give them more confidence to roll-out more clinical drug development programs in California.

Is OXIS International, Inc. (OTCMKTS:OXIS) Undervalued?

OXIS International, Inc. (OTCMKTS:OXIS) stock has been battered over the past 12 months even as itappears to have the key to cancer treatments. The company boasts of a robust portfolio of next generation cancer initiatives most of which have already shown prospects on positive clinical trials.

The company’s lead drug candidate is OXIS0-1550 has already shown success in human trials on the treatment of B-cell lymphoma or leukemia. The fact that the drug is designed to search and destroy cancer cells without any adverse effects sets the therapy apart from others already in use.

Supplementing OXIS International, Inc. (OTCMKTS:OXIS) pipeline of drugs is OXS-4235, which is a candidate treatment for Multiple Myeloma, a type of cancer found in white blood cells and affects up to 30,000 people in the US annually. The company is also working on OXS-2175 therapy designed to address triple negative breast cancer.